Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-09-28
2009-12-01
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C558S169000, C558S170000, C558S172000
Reexamination Certificate
active
07625882
ABSTRACT:
Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.
REFERENCES:
patent: 4329302 (1982-05-01), Hanahan et al.
patent: 4410237 (1983-10-01), Veldkamp
patent: 4614796 (1986-09-01), Kawamata et al.
patent: 4711512 (1987-12-01), Upatnieks
patent: 4827011 (1989-05-01), Wissner et al.
patent: 5061626 (1991-10-01), Baldo et al.
patent: 5082629 (1992-01-01), Burgess et al.
patent: 5224198 (1993-06-01), Jachimowicz et al.
patent: 5237451 (1993-08-01), Saxe
patent: 5660855 (1997-08-01), Male-Brune
patent: 5742262 (1998-04-01), Tabata et al.
patent: 5761177 (1998-06-01), Muneyoshi et al.
patent: 5835661 (1998-11-01), Tai et al.
patent: 6580529 (2003-06-01), Amitai et al.
patent: 6611385 (2003-08-01), Song
patent: 6805490 (2004-10-01), Levola
patent: 6822770 (2004-11-01), Takeyama
patent: 6833955 (2004-12-01), Niv
patent: 6838452 (2005-01-01), Harats et al.
patent: 7206107 (2007-04-01), Levola
patent: 2002/0158131 (2002-10-01), Dickson et al.
patent: 2003/0040509 (2003-02-01), Moskowitz
patent: 2003/0067685 (2003-04-01), Niv
patent: 2003/0202247 (2003-10-01), Niv et al.
patent: 2003/0225035 (2003-12-01), Harats et al.
patent: 2004/0051957 (2004-03-01), Liang
patent: 2004/0106677 (2004-06-01), Harats et al.
patent: 2005/0201693 (2005-09-01), Korenaga et al.
patent: 2005/0272813 (2005-12-01), Harats et al.
patent: 2006/0056028 (2006-03-01), Wildnauer
patent: 2006/0126179 (2006-06-01), Levola
patent: 2006/0194765 (2006-08-01), Garcia et al.
patent: 331167 (1992-07-01), None
patent: 1031870 (2000-08-01), None
patent: 1333308 (2003-08-01), None
patent: 1577872 (2005-09-01), None
patent: 60-104066 (1985-06-01), None
patent: 63054386 (1988-08-01), None
patent: 04-097201 (1992-03-01), None
patent: 06-230225 (1994-08-01), None
patent: 06-250022 (1994-09-01), None
patent: 07-258261 (1995-10-01), None
patent: WO 95/11473 (1995-04-01), None
patent: WO 95/23592 (1995-08-01), None
patent: WO 02/41827 (2002-05-01), None
patent: WO 03/032017 (2003-04-01), None
patent: WO 03/091763 (2003-11-01), None
patent: WO 2004/106486 (2004-09-01), None
patent: WO 2007/031991 (2007-03-01), None
patent: WO 2007/031992 (2007-03-01), None
Berchtold's, 1984, CAS: 101:130525.
Watson et al. “Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo”, Journal of Biological Chemistry, 272(21): 13597-13607, 1997. Esp. p. 13603.
Shaw et al. “Natural Antibodies With the T15 Idiotype May Act in Atherosclerosis, Apoptotic Clearance, and Protective Immunity,” The Journal of Clinical Investigation, 105(12): 1731-1740, 2000. Abstract. RN: 121324-31-0.
Subbanagounder et al. “Determinants of Bioactivity of Oxydized Phospholipids: Specific Oxidized Fatty Acyl Groups at the SN-2 Position,” Arteriosclerosis Thromb. Vasc. Biol., p. 2248-2254, 2000.
Boullier et al. “The Binding of Oxidized Low Density Lipoprotein to Mouse CD36 Is Mediated in Part by Oxidized Phospholipids That Are Associated With Both the Lipid and Protein Moieties of the Lipoprotein”, The Journal of Biological Chemistry, 275(13): 9163-9169, 2000. Esp. p. 9163, 9164.
Subbanagounder et al. “Evidence That Phospholipid Oxidation Products and/or Platelet-Activating Factor Play An Important Role in Early Atherogenesis: In Vitro and In Vivo Inhibitation by WEB 2086”, Circulation Research, p. 311-318, 1999. p. 311-313, 317.
Ota et al. “Complexes of ApoA-1 With Phosphatidylcholine Suppress Dysregulation of Arterial Tone by Oxidized LDL”, The American Journal of Physiology, 273(3 Pt.2): H1215-H1222. 1997.
Tokumura et al. “Cardiovascular Effects of Lysophophatidic Acid and Its Structural Analogs in Rats”, The Journal of Pharmacology and Experimental Therapeutics, 219(1): 219-222, 1981.
Leitinger et al. “Structurally Similar Oxidized Phospholipids Differentially Regulate Endothelial Binding of Monocytes and Neutrophils”, Proc. Natl. Acad. Sci. USA, 96(21): 12010-12015, 1999.
MacPherson et al. “Production and Characterization of Antibodies to Platelet-Activating Factor”, Journal of Lipid Mediators, 5(1): 49-59,1992. Abstract.
Wang et al. “A Facile Synthesis of an Aldehydic Analog of Platelet Activating Factor and Its Use in the Production of Specific Antibodies”, Chemistry and Physics of Lipids, 55(3): 265-273, 1990. Abstract.
Karasawa et al. “Antibodies to Synthetic Platelet-Activating Factor (1-0-Alky1-2-0-Acetyl-SN-Glycero-3-Phosphocholine) Analogs With Substituents at the SN-2 Position”, Journal of Biochemistry, 110(5): 683-687, 1991. Abstract.
Smal et al. “Production of Antibodies to Platelet Activating Factor”, Molecular Immunology, 26(8): 711-719, 1989.
Nitta et al. “Phospholipase A2 Activity of Fcγ2b Receptors of Thioglycollate-Elicited Murine Peritoneal Macropharges”, Journal of Leukocyte Biology, 36(4): 493-504, 1984. Abstract.
Berchthold et al. “Synthesis of Carboxyphospholipids”, Chemistry and Physics of Lipids, 28(1): 55-60, 1981. Abstract.
Cooney et al. “Combining Site Specificities of Rabbit Antibodies to Platelet-Activating Factor (PAF)”, Molecular Immunology, 27(5): 405-412, 1990. Abstract.
Kern et al. “Stimulation of Monocytes and Platelets by Short-Chain Phosphatidylcholines With and Without Terminal Carboxyl Group”, Biochimica et Biophysica Acta, 1394(1): 33-42, 1998. Abstract.
Anonymous “Graphic CIE L*a*b* Calculator. Try the Color Metric Converter or the RGB Calculator”, Applet, ColorEng Inc., Retrieved From the Internet: <URL: http://colorpro.com/info/tools/labcalc.htm>, 4 P., 2007.
Anonymus “TOPAS®: Thermoplastic Olefin Polymer of Amorphous Structure (COC). Cyclic Olefin Copolymer (COC)”, Polyplastics, Retrieved From the Internet: URL:http://www.polyplastics.com/en/product/lines/topas/TOPAS.pdf, p. 1-7, 2008.
Hoff et al. “Phospholipid Hydroxyaleknals: Biological and Chemical Properties of Specific Oxidized Lipids Present in Atherosclerotic Lesions”, Arteriosclerosis, Thrombosis, and Vascular Biology, 23: 275-282, 2003. p. 276, Fig. 1.
Podrez et al. “A Novel Family of Atherogenic Oxidized Phospholipids Promotes Macrophage Foam Cell Formation Via the Scavenger Receptor CD36 and Is Enriched in Atherosclerotic Lesions”, The Journal of Biological Chemistry, 277(41): 38517-38523, 2002. Scheme 1 on p. 38519.
Podrez et al. “Identification of a Novel Family of Oxidized Phospholipids That Serve as Ligands for the Macrophage Scavenger Recepter CD36”, The Journal of Biological Chemistry, 277(41): 38503-38516, 2002. Fig. 1, Table 1.
Subbanagounder et al. “Evidence That Phospholipid Oxidation Products and/or Platelet-Activating Factor Play An Important Role in Early Atherogenesis: In Vitro and In Vivo Inhibition by WEB 2086”, Circulation Research, 85: 311-318, 1999. Compound ‘PEIPC’.
Sung et al. “Analog Micro-Optics Fabrication by Use of A Binary Phase Grating Mask”, Micromachining Technology for Micro-Optics and Nano-Optics II, Proceedings of the SPIE, 5347(1): 62-70, 2004.
Thirstrup et al. “Diffractive Optical Coupling Element for Surface Plasmon Resonance Sensors”, Sensors and Actuators B, 100(3): 298-308, 2004.
Examiner's Report Dated Aug. 15, 2005 From the Australian Government, IP Australia Re.: Application No. 2002218461.
Notice of Allowance Dated Nov. 3, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/183,884.
Office Action Dated May 1, 2008 Fromthe Israeli Patent Office Re.: Application No. 172165.
Office Action Dated Aug. 12, 2008 From the Israeli Patent Office Re.: Application No. 172165.
Office Action Dated Jan. 14, 2008 From the Israeli Patent Office Re.: Application No. 172165.
Office Action Dated Oct. 17, 2008 Fro
George Jacob
Halperin Gideon
Harats Dror
Mendel Itzhak
Shiao Rei-tsang
Vascular Biogenics Ltd.
LandOfFree
Oxidized lipids and uses thereof in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxidized lipids and uses thereof in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxidized lipids and uses thereof in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4099686